PHOTO
Dubai: Takeda Pharmaceutical Company has signed a Memorandum of Understanding with the Ministry of Health and Prevention and Axios Health Education Services for implementation of the initiative to support patients who cannot financially afford to purchase part of their medications and who do not have a coverage system that includes the cost of the prescribed medications. The purpose of this MoU is to treat the relapses of some tumors and coloenteritis, as well as to improve patient commitment to the treatment plan prescribed by the attending physician.
His Excellency Dr. Amin Hussain Al Amiri, the Assistant Undersecretary for Public Health Policies and Licensing, signed the MoU on behalf of the MOHAP, in the presence of Dr. Ruqaya Al Bastaki, the Director of MOHAP’s Drug Department. while Mr. Takafumi Horii, the General Manager for the Middle East, signed on behalf of Takeda Pharmaceuticals, and Mr. Anas Al Safarini, the Executive Director of Axios Health Education Services, signed on behalf of Axios. The Memorandum of Understanding was signed in the presence of His Excellency Akihiko Nakajima; Ambassador Extraordinary and Plenipotentiary for Japan in United Arab Emirates.
Providing High-Quality Medications
This initiative comes within the framework of MOHAP's efforts to provide medications to low-income patients who are suffering from several diseases but have no access to insurance coverage, in order to alleviate their suffering. This Memorandum is intended to provide medications to patients who have relapsed or who are unresponsive to treatment in lymphocytes and Hodgkin's lymphoma, as well as patients with ulcerative colitis and Crohn's Disease (inflammatory bowel disease), through the provision of medications produced by Takeda and used to treat those diseases, free of charge. The amount of medication provided to each patient is estimated according to their ability to pay based on the case study of their financial situation conducted by Axios in cooperation with the charities licensed in the United Arab Emirates.
From the Japanese Embassy side; His Excellency Ambassador Nakajima highlighted the joint vision and cooperation strategy existing between the United Arab Emirates and Japan under a framework named “Comprehensive Strategic Partnership Initiative for Future Cooperation”.
In this context, it is important to build up tangible results in each area. His Excellency also highlighted “I’m very proud that the one of the biggest medical companies in Japan and MOHAP collaborate fulfilling patient needs”.
Alleviating Patients’ Suffering
Mr. Takafumi Hori expressed his pleasure to be co-operating with MOHAP to help patients gain access to medicines, regardless of their ability to afford the full cost of treatment, via Takeda’s Patient Assistance Programs. These programs have been designed to increase sustainable access to innovative medicines for complex and rare diseases.
-Ends-
About Takeda Pharmaceuticals
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience, and Rare Diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
For more information, visit https://www.takeda.com
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
